# Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS)

> **NCT02239120** · PHASE3 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 5390 (actual)

## Conditions studied

- Stroke
- Secondary Prevention

## Interventions

- **DRUG:** optional ASA as comedication
- **DRUG:** placebo to ASA
- **DRUG:** placebo to optional ASA as comedication
- **DRUG:** placebo to dabigatran etexilate
- **DRUG:** ASA 100 mg
- **DRUG:** dabigatran etexilate

## Key facts

- **NCT ID:** NCT02239120
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-11-27
- **Primary completion:** 2018-08-14
- **Final completion:** 2018-08-14
- **Target enrollment:** 5390 (ACTUAL)
- **Last updated:** 2019-09-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02239120

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02239120, "Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02239120. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*